Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study
|
|
- Meryl McKinney
- 5 years ago
- Views:
Transcription
1 Ito et al. Journal of Pharmaceutical Health Care and Sciences (2018) 4:28 RESEARCH ARTICLE Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study Takahiro Ito 1, Kazuhiro Yamamoto 1, Fuminori Ohsawa 1, Ikuo Otsuka 2, Akitoyo Hishimoto 2, Ichiro Sora 2, Midori Hirai 1 and Ikuko Yano 1* Open Access Abstract Background: Risperidone is mainly metabolized by cytochrome P450 (CYP) 2D6 in the liver. The gene encoding CYP2D6 is highly polymorphic. The average steady-state plasma concentration of risperidone active moiety is higher in the CYP2D6 intermediate metabolizers (IMs) compared with that in the extensive metabolizers (EMs). An association between drug-induced extrapyramidal symptoms scale (DIEPSS) score and CYP2D6 polymorphisms has not been reported to date. This study investigates the association of CYP2D6 polymorphisms with the severity of extrapyramidal symptoms in schizophrenia patients receiving risperidone therapy. Methods: Schizophrenia patients undergoing risperidone treatment were recruited for the study in the Kobe University Hospital. We evaluated extrapyramidal symptoms of schizophrenia using the DIEPSS. CYP2D6*10 and CYP2D6*14 were analyzed using TaqMan assays, and CYP2D6*5 was analyzed using the long-pcr method. Patients with CYP2D6*1/*5, *1/*14, *5/*10, *10/*10, and*10/*14 were classified as IMs, and patients with CYP2D6*1/*1 and *1/*10 were classified as EMs. Patients with CYP2D6*5/*5, *5/*14, and*14/*14 were classified as poor metabolizers (PMs). Results: A total of 22 patients were included in the study. No patients were classified as PMs. The dose of risperidone (mg/day) was not significantly different between EMs (n =15)andIMs(n = 7) (median with the interquartile range: 4.0 ( ) vs. 4.0 ( ) mg, p = 0.31). The age and disease duration of schizophrenia were not significantly different between the EMs and IMs. The DIEPSS score in the IMs was significantly higher than that in the EMs (median with the interquartile range: 5.0 ( ) vs. 0.0 ( ), p < 0.001). The multiple regression analysis showed that CYP2D6 IMs is a significant risk factor for the DIEPSS (p < 0.05). Conclusion: Special attentions should be paid to the onset of extrapyramidal symptoms in schizophrenia patients identified as CYP2D6 IM undergoing risperidone therapy. Keywords: Schizophrenia, Extrapyramidal symptoms, DIEPSS, CYP2D6, Risperidone * Correspondence: iyano@med.kobe-u.ac.jp 1 Department of Pharmacy, Kobe University Hospital, Kusunoki-cho, Chuo-ku, Kobe , Japan Full list of author information is available at the end of the article The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.
2 Ito et al. Journal of Pharmaceutical Health Care and Sciences (2018) 4:28 Page 2 of 6 Background The advent of typical antipsychotic medications such as chlorpromazine revolutionized schizophrenia treatment in the 1950s [1]. Atypical antipsychotics developed after 1960s showed a relatively low frequency of extrapyramidal symptoms. The atypical antipsychotic risperidone has a high binding affinity for both dopamine D 2 and serotonin 5-HT 2 receptors and has a proven efficacy in the treatment of schizophrenic positive and negative symptomatology [2]. In the late years, although the atypical antipsychotics such as clozapine and risperidone that relatively had low frequency of extrapyramidal symptoms are used, many patients develop serious acute adverse effects, such as akathisia, dystonia, and parkinsonism, leading to an impaired quality of life of these patients [3 5]. In addition, insufficient management of the adverse effects due to the antipsychotics increases the patients mortality [6]. Risperidone is mainly metabolized to the active metabolite 9-hydroxy-risperidone by cytochrome P450 (CYP) 2D6 in the liver [7]. Previous pharmacokinetic studies of risperidone have revealed a large interindividual variability between oral dose and actual plasma concentrations [8]. Physiological factors such as age and body weight have been implicated in this variability. In addition, since the gene encoding CYP2D6 is highly polymorphic [9], CYP2D6 status might affect as well risperidone pharmacokinetics. Four phenotypes of CYP2D6 have been defined as follows: (1) poor metabolizers (PMs), without enzyme activity; (2) intermediate metabolizers (IMs), with reduced enzyme activity; (3) extensive metabolizers (EMs), with normal activity; and (4) ultra-rapid metabolizers, with increased enzyme activity [9]. In the Japanese population, EMs are observed at the highest frequency and include CYP2D6*1/*1 (17.8%), *1/*2 (11.2%), *1/*10 (29.7%), and *2/*10 (7.7%) [10]. Genotypes classified into PM is rare in the Japanese population, whereas CYP2D6*1/*5 (6.3%), *5/ *10 (5.2%), and *10/*10 (14.3%) classified into IM represent about one quarter [10]. CYP2D6*14 as well as CYP2D6*5 are reported as the major defective alleles found in Japanese subjects [11]. The frequencies of CYP2D6*5 and *14 were 6.2 and 2.2%, respectively [11]. The area under the concentration-time curve of risperidone in IMs is reported higher than that in EMs [12]. Findings regarding the association between CYP2D6 polymorphisms and response to risperidone have been conflicting [13]. On the other hand, higher plasma concentrations of risperidone plus 9-hydroxy-risperidone, the active moiety of risperidone, are associated with higher incidence of adverse effects [14]. Thus, CYP2D6 genotyping might be useful in personalizing risperidone therapy in patients with schizophrenia to reduce the incidence of adverse extrapyramidal symptoms. A drug-induced extrapyramidal symptoms scale (DIEPSS) was developed in Japan in 1994 for evaluating the symptoms seen in psychiatry patients taking antipsychotics [15]. DIEPSS is suitable to evaluate the low incidence of extrapyramidal symptoms occurring during the treatment with atypical antipsychotics such as risperidone [16, 17]. DIEPSS was reported having high inter-rater and test-retest reliability, and a concurrent validity with other rating scales for extrapyramidal symptoms [18]. In the present study, our objective was to investigate the association of CYP2D6 polymorphisms with the severity of extrapyramidal symptoms in schizophrenia patients receiving risperidone therapy. Methods Patients Patients with schizophrenia defined according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria [19] who received risperidone treatment were recruited for the study between February 2011 and July 2013 from the Kobe University Hospital. Patients were eligible for the study if DIEPSS data were available. Patient information including age, disease duration of schizophrenia, gender, body weight, laboratory data, and history of prescription was collected from the electronic medical records. Ethics approval This study was designed and implemented in accordance with the Declaration of Helsinki and its amendments. The present study was approved by the Ethics Committee of the Kobe University Graduate School of Medicine for Genetic Analysis (No. 57). Written informed consent was obtained from each patient registered in the study. Evaluation of extrapyramidal symptoms The extrapyramidal symptoms in each patient were evaluated using the DIEPSS by the attending psychiatrists in Kobe University Hospital when the patient received risperidone maintenance dose. Since risperidone reaches a steady-state within 2 weeks, we evaluated DIEPSS score after day 14 from the start of risperidone therapy. DIEPSS consists of one global item (overall severity) and eight individual items (gait, bradykinesia, sialorrhea, muscle rigidity, tremor, akathisia, dystonia, and dyskinesia); each item is rated on a five-point scale (0, normal; 1, minimal; 2, mild; 3, moderate; 4, severe) [15]. The primary endpoint in this study was the sum score of the nine items. CYP2D6 genotyping For each participant, we collected peripheral blood samples in EDTA tubes, which were kept at 80 C until use. Genomic DNA was extracted with the QIAamp DNA Blood Midi Kit (Qiagen Inc., Valencia, CA, USA) according to the manufacturer s instructions. CYP2D6*10
3 Ito et al. Journal of Pharmaceutical Health Care and Sciences (2018) 4:28 Page 3 of 6 (rs ) and CYP2D6*14 (rs ) were analyzed using commercially available TaqMan assays (Applied Biosystems, Foster, CA, USA). CYP2D6*5 (CYP2D6 deletion) was analyzed using the long-pcr method [20]. The distinction of CYP2D6*5/*10 and *10/*10 was not analyzed in this study. On the basis of the previous study [9, 11], patients with CYP2D6*1/*5, *1/*14, *5/*10, *10/*10, and*10/ *14 were classified as IMs. Patients with CYP2D6*1/*1 and *1/*10 were classified as EMs. Patients with CYP2D6*5/*5, *5/*14, and*14/*14 were classified as PMs. Statistical analysis All statistical analyzes were performed using SPSS Statistics 24.0 (IBM Japan, Tokyo, Japan). Data are expressed as the number of patients or the median with interquartile range. Fisher s exact tests were used to test the distribution of categorical data, whereas Mann Whitney U tests were employed to compare the medians of continuous values between groups. Regression analysis was performed to evaluate the relationship between risperidone dose and DIEPSS score. Multiple regression analysis was performed to identify factors affecting the DIEPSS score, in which the DIEPSS score was defined as the dependent variable, and all the independent variables (p < 0.2) defined in the univariate analysis were selected and tested. P values less than 0.05 were considered statistically significant. Results A total of 33 patients were recruited from February 2011 to July 2013 and provided written informed consent. Twenty-two patients whose DIEPSS data were available were eligible for the study. Table 1 shows the demographic and clinical characteristics of 22 schizophrenia patients treated with risperidone. The CYP2D6*1/*1, *1/ *5, *1/*10, and *5/*10 or *10/*10 genotypes were detected in 2, 2, 13, and 5 patients respectively. Seven patients with CYP2D6*1/*5, *5/*10, and *10/*10 were classified as IMs, and 15 patients with CYP2D6*1/*1 and *1/*10 were classified as EMs. CYP2D6*5/*5 genotype and *14 allele were not detected in any patient in this study. The dose of risperidone (mg/day) was not Table 1 Patient demographics EM (n = 15) IM (n =7) p Age (years) 33.0 ( ) 39.0 ( ) 0.56 a Disease duration of schizophrenia (years) 12.0 ( ) 9.0 ( ) 0.43 a Gender: female/male 7/8 4/ b Body weight (kg) 63.0 ( ) 64.2 ( ) 0.96 a Laboratory data AST (IU/L) 20 (16 23) 24 (19 32) 0.31 a ALT (IU/L) 24 (14 33) 22 (17 94) 0.71 a Albumin (g/dl) 4.5 ( ) 4.5 ( ) 0.49 a Bilirubin (mg/dl) 0.60 ( ) 0.60 ( ) 0.32 a Serum creatinine (mg/dl) 0.79 ( ) 0.74 ( ) 0.37 a egfr (ml/min/1.73 m 2 ) 79.3 ( ) 85.0 ( ) 0.64 a Antipsychotics Risperidone dose (mg/day) 4.0 ( ) 4.0 ( ) 0.31 a Risperidone dose (mg/kg) ( ) ( ) 0.55 a Olanzapine (+/ ) 4/11 2/ b Levomepromazine (+/ ) 5/10 1/ b Chlorpromazine equivalent dose (mg/day) 500 ( ) 475 ( ) 0.79 a Other treatments Number of concomitant drugs 4 (2 5) 7 (2 8) 0.31 a Anticholinergics (+/ ) 7/8 5/ b Mood stabilizers (+/ ) 4/11 3/ b Benzodiazepines (+/ ) 12/3 6/ b Data are expressed as the number of patients or median with the interquartile range in parentheses Two cases (one case in the EM group, the other case in the IM group) were excluded in the body weight and risperidone dose (mg/kg) data, because information on the body weight was not obtained a Mann Whitney U test b Fisher s exact test EM extensive metabolizer, IM intermediate metabolizer, AST aspartate aminotransferase, ALT alanine aminotransferase, egfr estimated glomerular filtration rate
4 Ito et al. Journal of Pharmaceutical Health Care and Sciences (2018) 4:28 Page 4 of 6 significantly different between EM and IM groups (median: 4.0 ( ) vs. 4.0 ( ) mg, p = 0.31). None of the patients had advanced renal dysfunction or liver dysfunction. Median levels of aspartate aminotransferase, alanine aminotransferase, and serum creatinine were in the reference ranges of our hospital for both the EM and IM groups. The age, disease duration of schizophrenia, body weight, and the number of concomitant drugs were not significantly different between EM and IM groups. Although 15 patients (68.2%) concomitantly used other antipsychotics except risperidone, the total of chlorpromazine equivalent dose (mg/day) was not significantly different between EM and IM groups (median: 500 ( ) vs. 475 ( ) mg, p =0.79). In this study, olanzapine and levomepromazine were each used in six patients (27.3%), aripiprazole and chlorpromazine were each used in three patients (13.6%), quetiapine, zotepine, paliperidone, and blonanserin were each used in two patients (9.1%), and sulpiride was used in one patient (4.5%). None of the patients had a medical history of Parkinson s disease. Paroxetine, a potent CYP2D6 inhibitor, was concomitantly used in one patient in the EM group. Onset of extrapyramidal symptoms (DIEPSS score 1) was observed in 13 (59.1%) out of the 22 patients. The DIEPSS score in the IM group was significantly higher than that in EM group (Fig. 1; median: 5.0 ( ) vs. 0.0 ( ), p < 0.001). No significant correlation was observed between the DIEPSS score and risperidone dose corrected by body weight when all patients were included in the analysis. (Fig. 2; y = 5.55x , R 2 =0.006, p = 0.749). Also, no significant correlation was observed between the DIEPSS score and risperidone doses (mg/kg) when the regression analysis is conducted for each genotype (Fig. 2; y= 34.33x , R 2 =0.176,p = in the EM group, y = 20.85x , R 2 =0.297, p = in the IM group). Multiple regression analysis was performed to identify factors affecting the DIEPSS [DIEPSS = age (years) 4.15 bilirubin (mg/dl) 4.77 serum creatinine (mg/dl) CYP2D6 status (IM = 1 and EM = 0)] (Table 2). CYP2D6 IM was proven to be a significant factor affecting the DIEPSS (p <0.05). Discussion Among 22 patients, extrapyramidal symptoms (DIEPSS score 1) were determined in 13 patients (59.1%), demonstrating a strong association between adverse drug effects and the risperidone therapy, opposite to the relatively low frequency reported. The DIEPSS score in the CYP2D6 IM group was significantly higher than that in EM group in this study, while we found no difference in risperidone dosing corrected by body weight between the two groups. Since adverse reactions can be correlated with risperidone concentrations, the 2017 consensus guidelines in neuropsychopharmacology recommend therapeutic drug monitoring for patients treated with risperidone [21]. To avoid neurological adverse reactions, risperidone doses which achieve over 40 ng/ml risperidone plus 9-hydroxy-risperidone plasma concentration should only be administrated in cases of insufficient or absence of therapeutic response [21]. Unfortunately, we did not Fig. 1 Influence of CYP2D6 genotype on DIEPSS score. The box plot shows minimum, first quartile, median, third quartile, and maximum. The central rectangle spans the first quartile to the third quartile (the interquartile range). An outlier between 1.5 and 3 times the interquartile range is shown as an open circle. Statistical analysis was performed using the Mann Whitney U test Fig. 2 Correlation between risperidone dose per body weight and DIEPSS score. Two cases were excluded because information on the body weight was not obtained
5 Ito et al. Journal of Pharmaceutical Health Care and Sciences (2018) 4:28 Page 5 of 6 Table 2 Predictive factors for the DIEPSS score Factors B Std. error p Constant Age Bilirubin Serum creatinine CYP2D6 IM * The F score of this model was 4.24 (p = 0.016) with adjusted R 2 = B unstandardized coefficients, IM intermediate metabolizer * p < 0.05 was considered statistically significant perform plasma concentration measurements of risperidone and the subsequent dose adjustments in this study. On the basis of simulation results in a typical patient (body weight of 70 kg and creatinine clearance of 120 ml/min) on stable therapy with risperidone 2 mg twice daily (4 mg/day), the average steady-state plasma concentration of risperidone active moiety in the IM group is approximately 40 ng/ml and 1.6-fold higher compared with patients with CYP2D6*1/*1 genotype [8]. Although pharmacokinetics of risperidone and its active metabolite are affected by age, gender, body weight, smoking habits, co-administered drugs, and CYP2D6 genotype [14], the patient characteristics such as age, body weight, and laboratory data were not significantly different between EM and IM groups in this study. Disease duration of schizophrenia can affect the severity of extrapyramidal symptoms, but there were no significant differences between EM and IM groups. Additionally, the results in this study were similar even if one patient who used paroxetine was excluded (data not shown). Therefore, we speculate that the decrease in the clearance of risperidone in the IM group causes an increased risperidone plasma concentration, which increases the severity of the extrapyramidal symptoms. This is the first report to show an association between DIEPSS score and CYP2D6 polymorphism. In this study, no significant correlation was obtained between the DIEPSS score and risperidone dose corrected by the body weight when the regression analysis is conducted for all patients or each genotype. A previous study showed a weak but significant correlation between oral risperidone dose and plasma concentrations of the active moiety [22]. On the other hand, pharmacokinetics of risperidone and its active metabolite are affected by age, gender, body weight, smoking habits, and co-administered drugs in addition to CYP2D6 genotype [14]. Therefore, we consider that the sum of plasma concentrations of risperidone and 9-hydroxy-risperidone cannot be precisely predicted by the risperidone dose only. Moreover, we consider that the sample size in this study might be insufficient to detect the relationship between the DIEPSS score and risperidone doses, and there might be other risk factors of higher DIEPSS to explain why the DIEPSS score and risperidone dose are not correlated in our study. The results of multiple regression analysis show that CYP2D6 polymorphism is the only significant factor to be correlated with the DIEPSS. Since the sample size in this study is relatively small, any effects of other previously reported factors influencing the pharmacokinetics and pharmacodynamics of risperidone remain to be clarified with a larger number of patients. Several limitations of this study should be acknowledged. This study is a retrospective study based on medical records, and we did not measure the plasma concentration of risperidone and active metabolite 9-hydroxy-risperidone. In a future prospective study, it is necessary to clarify the relationship among CYP2D6 polymorphism, plasma concentrations of risperidone and its metabolite, pharmacological effects, and the severity of adverse effects in Japanese patients. In addition, detailed information on the duration from the start of risperidone to scoring DIEPSS was not available in this study, and 15 patients (68.2%) concomitantly used antipsychotics beside risperidone. Therefore, a prospective study should be conducted including patients on newly risperidone monotherapy to exclude the potential influence of the duration of risperidone treatment and other antipsychotics on the result interpretation. Conclusions The DIEPSS score was significantly higher in the CYP2D6 IM group compared with in the EM group. The role of CYP2D6 genotyping in personalizing risperidone therapy in patients with schizophrenia should be examined in a prospective study using plasma concentration measurements of risperidone and 9-hydroxy-risperidone. Abbreviations ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CYP: Cytochrome P450; DIEPSS: Drug-induced extrapyramidal symptoms scale; DSM: Diagnostic and Statistical Manual of Mental Disorders; egfr: Estimated glomerular filtration rate; EMs: Extensive metabolizers; IMs: Intermediate metabolizers; PMs: Poor metabolizers Acknowledgements We are grateful to all participating patients as well as cooperating physicians, pharmacists, and other medical professionals at Kobe University Hospital. Funding This work was supported by the Research Foundation for Pharmaceutical Sciences (Japan). Availability of data and materials The data will not be shared because of human data. Authors contributions TI, KY, and IY conceived the study, designed the protocol. TI, KY, and FO carried out the study. TI, KY, and IY drafted the manuscript. IO and AH obtained the informed consent from each patient and participated in the data acquisition. FO, IO, AH, IS, and MH participated in interpretation of the data and contributed the discussions. All authors read and approved the final manuscript.
6 Ito et al. Journal of Pharmaceutical Health Care and Sciences (2018) 4:28 Page 6 of 6 Ethics approval and consent to participate The present study was approved by the Ethics Committee of the Kobe University Graduate School of Medicine for Genetic Analysis (No. 57). Written informed consent was obtained from each patient registered in the study. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Publisher s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Author details 1 Department of Pharmacy, Kobe University Hospital, Kusunoki-cho, Chuo-ku, Kobe , Japan. 2 Department of Psychiatry, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe , Japan. Received: 31 August 2018 Accepted: 7 November Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res. 2002;57(2 3): Inada T. A second-generation rating scale for antipsychotic-induced extrapyramidal symptoms: drug-induced extrapyramidal symptoms scale. Tokyo: Seiwa Shoten Publishers; Kim JH, Jung HY, Kang UG, Jeong SH, Ahn YM, Byun HJ, et al. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders. Mov Disord. 2002;17(6): Association AP. Diagnostic and Statistical manual of mental disorders. fourth ed. Washington, DC: American Psychiatric Association; Okubo M, Murayama N, Miura J, Shimizu M, Yamazaki H. A rapid multiplex PCR assay that can reliably discriminate the cytochrome P450 2D6 whole-gene deletion allele from 2D6*10 alleles. Clin Chim Acta. 2012;413(19 20): Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in Neuropsychopharmacology: update Pharmacopsychiatry. 2018;51(1 02): Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Müller-Arends A, Weber K, et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci. 2005;255(4): References 1. Delay J, Deniker P, Ropert R. Four years of experience with chlorpromazine in therapy of psychoses. Presse Med. 1956;64(22): Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs. 2011;71(2): Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1): Kose E, Uno K, Hayashi H. Evaluation of the expression profile of extrapyramidal symptoms due to antipsychotics by data mining of Japanese adverse drug event report (JADER) database. Yakugaku Zasshi. 2017;137(1): de Araújo AA, de Araújo Dantas D, do Nascimento GG, Ribeiro SB, Chaves KM, de Lima Silva V, et al. Quality of life in patients with schizophrenia: the impact of socio-economic factors and adverse effects of atypical antipsychotics drugs. Psychiatr Q. 2014;85(3): Uçok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008;7(1): Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry. 2007; 12(8): Locatelli I, Kastelic M, Koprivsek J, Kores-Plesnicar B, Mrhar A, Dolzan V, et al. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. Eur J Pharm Sci. 2010;41(2): Cabaleiro T, Ochoa D, Román M, Moreno I, López-Rodríguez R, Novalbos J, et al. Polymorphisms in CYP2D6 have a greater effect on variability of risperidone pharmacokinetics than gender. Basic Clin Pharmacol Toxicol. 2015;116(2): Ebisawa A, Hiratsuka M, Sakuyama K, Konno Y, Sasaki T, Mizugaki M. Two novel single nucleotide polymorphisms (SNPs) of the CYP2D6 gene in Japanese individuals. Drug Metab Pharmacokinet. 2005;20(4): Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol. 2000;50(1): Yoo HD, Cho HY, Lee SN, Yoon H, Lee YB. Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. J Pharmacokinet Pharmacodyn. 2012;39(4): Spina E, de Leon J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm (Vienna). 2015;122(1): Urban AE, Cubała WJ. Therapeutic drug monitoring of atypical antipsychotics. Psychiatr Pol. 2017;51(6): Inada T. Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to its usage. Tokyo: Seiwa Shoten Publishers; 1996.
Antipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationTherapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?
Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Prof. Dr. Christoph Hiemke Psychiatrische Klinik und Poliklinik Universität Mainz Psychopharmacotherapy Psychiatric Patient
More informationRisperidone Case 1: Drug-Drug Interactions
Risperidone Case 1: Drug-Drug Interactions 1-14-16 de Leon & Bork (a resident) J Clin Psychiatry 1997;58:450-1 http://www.ncbi.nlm.nih.gov/pubmed/9375597 Jose de Leon, MD Educational Objectives At the
More informationEffects of Discontinuation of Paliperidone Long-Acting Injectable After Switching from Risperidone Long-Acting Injectable Switching
Evidence-Based Medicine Key Words: antipsychotics, paliperidone palmitate, risperidone, long-acting injectable, successful switching, discontinuation Effects of Discontinuation of Paliperidone Long-Acting
More informationRisperidone (RIS) is metabolized primarily by 9-hydroxylation
BRIEF REPORT Effects of CYP2D6 and CYP3A5 Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients Rhee-Hun Kang, MD, PhD,* Sun-Min Jung, MD, PhD,þ
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationA 52-week, randomized, open-label study of aripiprazole versus blonanserin in the treatment of Japanese schizophrenia patients
Original Contribution CNPT8(2017)16-24 A 52-week, randomized, open-label study of aripiprazole versus blonanserin in the treatment of Japanese schizophrenia patients Asuka Katsuki, Hikaru Hori, Kiyokazu
More informationGeneral Discussion 4
General Discussion 4 General Discussion 115 Introduction Psychiatry is considered to be one of the first medical disciplines that will implement pharmacogenetic testing in daily clinical practice. The
More informationMental Health DNA Insight WHITE PAPER
Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,
More information) and serotonin Type 2 (5-HT 2A
Latuda (lurasidone HCl) Fact Sheet Schizophrenia FREQUENTLY ASKED QUESTIONS What type of patient with schizophrenia is appropriate for LATUDA? LATUDA is an atypical antipsychotic agent indicated for the
More informationPharmacogenomics of Medications for Pain and Major Depression: Promise and Peril
Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP Professor of Clinical Sciences Drake University College of Pharmacy and Health
More informationPharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia
Pharmacokinetics Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia The Journal of Clinical Pharmacology 2018, 58(1) 74 80 C 2017,
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationClozapine Case 6: Half-Life Jose de Leon, MD
Clozapine Case 6: Half-Life 1-16-16 Jose de Leon, MD 6. Clozapine Case 6 J Clin Psychopharmacol 1996;16:193-4. http://www.ncbi.nlm.nih.gov/pubmed/8690839 Educational Objectives At the conclusion of this
More informationPharmacogenomics and Customized Therapies in Psychiatry
Pharmacogenomics and Customized Therapies in Psychiatry Toshiyuki Someya,, MD, PhD Department of Psychiatry Niigata University Graduate School of Medical and Dental Sciences The efficacy and side effects
More informationPEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationFL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components
More informationIn February 2013, the FDA approved a
Long-acting injectable aripiprazole for adult schizophrenia Jana Lincoln, MD Depot formulation and once-monthly dosing might improve adherence in patients with schizophrenia 46 May 2013 In February 2013,
More informationUniversity of Groningen. Pharmacy data as a tool for assessing antipsychotic drug use Rijcken, Claudia
University of Groningen Pharmacy data as a tool for assessing antipsychotic drug use Rijcken, Claudia IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to
More informationThey deserve personalized treatment
Your patients are unique They deserve personalized treatment New laboratory service offered by STA 2 R is a panel of genetic tests that gives prescribers answers to the clinical questions below. The test
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationMental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service
Mental Health Medicines Management Pilot Community Pharmacy High Dose Antipsychotic Screening, Education & Advice Service Approved Version 1 Date of First Issue Review Date Date of Issue Author / Contact
More informationUniversity of Groningen. Neurological soft signs in schizophrenia and mood disorders Boks, Marco Paul Maria
University of Groningen Neurological soft signs in schizophrenia and mood disorders Boks, Marco Paul Maria IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationSafe and Effective Use of. Psychotropic Drugs. Introduction. Psychotropic Drugs. Jun NAKAMURA
Psychotropic Drugs Safe and Effective Use of Psychotropic Drugs JMAJ 47(6): 259 264, 2004 Jun NAKAMURA Professor, Department of Psychiatry, School of Medicine, University of Occupational and Environmental
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Rexulti) Reference Number: NE.PMN.68 Effective Date: 01/01/2017 Last Review Date: Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationCYP2D6: mirtazapine 2001/2002/2003
CYP2D6: mirtazapine 2001/2002/200 Cl or = oral clearance,=c ss = steady state concentration, EM = extensive metaboliser, IM = intermediate metaboliser, MR = metabolic ratio, NS = non-significant, PM =
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationTable of Contents. 1.0 Policy Statement...1
Division of Medical Assistance General Clinical Policy No. A-6 Table of Contents 1.0 Policy Statement...1 2.0 Policy Guidelines...1 2.1 Eligible Recipients...1 2.1.1 General Provisions...1 2.1.2 EPSDT
More informationComparison of the Defined Daily Dose and Chlorpromazine Equivalent Methods in Antipsychotic Drug Utilization in Six Asian Countries
Research Comparison of the Defined Daily Dose and Chlorpromazine Equivalent Methods in Antipsychotic Drug Utilization in Six Asian Countries Shih-Ku Lin 1,2,, Yen-Feng Lin 1, Shu-Yu Yang 1, Yan-Ling He
More informationRecent experiences to review data from MRCTs and progress of research on ethnic factors. Dr Yoshiaki Uyama
Recent experiences to review data from MRCTs and progress of research on ethnic factors Dr Yoshiaki Uyama (PMDA) Visiting Professor, Graduate School of Advanced Clinical Science, Chiba University Visiting
More informationLurasidone: A New Antipsychotic For Schizophrenia. Objectives. Introduction. Pharmacology/Pharmacokinetics. Mechanism of Action. Mechanism of Action
Lurasidone: A New Antipsychotic For Schizophrenia Theodore Pikoulas, PharmD PGY2 Psychiatric Pharmacy Resident Louis Stokes Cleveland VAMC Objectives Review the pharmacology and the pharmacokinetics Identify
More informationMembership Overview: Total Members: 322 Student Members: 160 Resident Members: 8 Fellow Members: 4
A Closer Look at the Central Nervous System PRN Overview of the PRN The Central Nervous System Practice and Research Network (CNS PRN) provides a forum to encourage networking among pharmacists specializing
More informationCHLORPROMAZINE EQUIVALENTS VERSUS DEFINED DAILY DOSES: HOW TO COMPARE ANTIPSYCHOTIC DRUG DOSES?
CHLORPROMAZINE EQUIVALENTS VERSUS DEFINED DAILY DOSES: HOW TO COMPARE ANTIPSYCHOTIC DRUG DOSES? C.A.W. Rijcken 1, T.B.M. Monster 1, J.R.B.J. Brouwers 1, L.T.W. de Jong van den Berg 1 1 Department of Social
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Rexulti) Reference Number: CP.PMN.68 Effective Date: 11.05.15 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationPlasma ammonia levels in patients treated with valproic acid
Research Plasma ammonia levels in patients treated with valproic acid Hirofumi Tesen 1, Asuka Katsuki 1, Hikaru Hori 1, Kiyokazu Atake 1, Reiji Yoshimura,1, Jun Nakamura 1 ABSTRACT Objective: Valproic
More informationPharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
More informationClinically Relevant Interactions between Newer Antidepressants and Second-Generation Antipsychotics
University of Kentucky UKnowledge Psychiatry Faculty Publications Psychiatry 5-2014 Clinically Relevant Interactions between Newer Antidepressants and Second-Generation Antipsychotics Edoardo Spina University
More informationShuma Hirashio 1,2, Shigehiro Doi 1 and Takao Masaki 1*
Hirashio et al. Renal Replacement Therapy (2018) 4:24 https://doi.org/10.1186/s41100-018-0164-9 CASE REPORT Open Access Magnetic resonance imaging is effective for evaluating the therapeutic effect of
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationSafety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents
Pediatr Drugs (2013) 15:217 233 DOI 10.1007/s40272-013-0024-6 REVIEW ARTICLE Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents Silvio Caccia Published online: 16 April
More informationPORT, 2009 Spain, 2009 Malaysia, 2009 Singapore, 2009 BAP, 2011 WFSBP, 2012 SIGN, 2013 Harvard NICE RANZCP, 2016
Appendix 3. Comparison of recommendations from clinical practice guidelines. Data extracted in relation to key health questions that are relevant to a clinician adopting an algorithmic approach to the
More informationMethod. NeuRA First versus second generation antipsychotics August 2016
Introduction First generation typical are an older class of antipsychotic than second generation atypical. First generation are used primarily to treat positive symptoms including the experiences of perceptual
More informationCariprazine is a newly approved
Cariprazine for schizophrenia and bipolar I disorder Gregory Mattingly, MD, and Richard Anderson, MD, PhD Cariprazine is a newly approved (September 2015) dopamine D3/D2 receptor partial agonist with higher
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.59 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at the
More informationAustedo. Austedo (deutetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.15 Subject: Austedo Page: 1 of 6 Last Review Date: September 15, 2017 Austedo Description Austedo
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Single Technology Appraisal Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents
More informationRole of Clozapine in Treatment-Resistant Schizophrenia
Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant
More informationPharmacogenetics and Antipsychotic Treatment in Schizophrenia with Special Focus on Adverse Drug Reactions
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 335 Pharmacogenetics and Antipsychotic Treatment in Schizophrenia with Special Focus on Adverse Drug Reactions ARZU
More informationChapter 161 Antipsychotics
Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in
More informationTrends of kidney transplantation in Japan in 2018: data from the kidney transplant registry
Yagisawa et al. Renal Replacement Therapy (2019) 5:3 https://doi.org/10.1186/s41100-019-0199-6 POSITION STATEMENT Trends of kidney transplantation in Japan in 2018: data from the kidney transplant registry
More informationAssociation Between Serum Anticholinergic Activity and Psychiatric Symptoms of Chronic Schizophrenia
Showa Univ J Med Sci 27 4, 251 260, December 2015 Original Association Between Serum Anticholinergic Activity and Psychiatric Symptoms of Chronic Schizophrenia Norihisa AKASHI 1, Masayuki TANI 1, Takahiro
More information( delirium ) 15%- ( extrapyramidal syndrome ) risperidone olanzapine ( extrapyramidal side effect ) olanzapine ( Delirium Rating Scale, DRS )
2005 6 48-52 Olanzapine 30% ( delirium 5%- Haloperidol ( extrapyramidal syndrome risperidone ( extrapyramidal side effect ( Delirium Rating Scale, DRS ( Delirium ( Olanzapine ( Delirium Rating Scale, DRS
More informationIntuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes
(2010), 1 5 & 2010 Macmillan Publishers Limited. All rights reserved 1470-269X/10 www.nature.com/tpj ORIGINAL ARTICLE Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5
More informationPharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects
Pharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects Dr. Francisco Abad Santos 16 June 2017 Atypical antipsychotics or second generation antipsychotics
More informationObjectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia
Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used
More informationJun Ishigooka 1*, Kazuyuki Nakagome 2, Tetsuro Ohmori 3 and Nakao Iwata 4
Ishigooka et al. BMC Psychiatry 2013, 13:243 STUDY PROTOCOL Open Access Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationAlternative Thresholds for Negative and Positive Symptoms in the CATIE Trial: Implications for Negative Symptom Clinical Trials
Alternative Thresholds for Negative and Positive Symptoms in the CATIE Trial: Implications for Negative Symptom Clinical Trials Eduardo Dunayevich, Chao-Yin Chen, Stephen Marder and Jonathan Rabinowitz
More informationpaliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd
Re-Submission paliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd 07 October 2011 The Scottish Medicines Consortium
More informationDetermination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone
Citation: CPT Pharmacometrics Syst. Pharmacol. (), ; VC ASCPT All rights reserved doi:./psp. ORIGINAL ARTICLE Determination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone J Korell,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 List of medicines concerned: SECOND-GENERATION ORAL ANTIPSYCHOTICS SOLIAN 100 mg, 200 mg, 400 mg
More informationCocaine is a Major Risk Factor for Antipsychotic Induced Akathisia, Parkinsonism and Dyskinesia By Arija Maat, Annemarie Fouwels, Lieuwe de Haan
PB-41-3-2008-De haan.qxp 09-09-2008 15:45 Page 5 ORIGINAL RESEARCH Key Words: cannabis, cocaine, drug abuse, extrapyramidal side effects, neuroleptics, antipsychotics Cocaine is a Major Risk Factor for
More informationAnti-psychotic Polypharmacy in the Treatment of Patients with Resistant Schizophrenia: A Descriptive Study
Research Reviews: Pharmacy & Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Anti-psychotic Polypharmacy in the Treatment of Patients with Resistant Schizophrenia: A Descriptive Study Etwal Bou
More informationMichael J. Bailey, M.D. OptumHealth Public Sector
Michael J. Bailey, M.D. OptumHealth Public Sector LIHP Quality Charter To ensure the quality of care delivered to enrollees in San Diego County Assistance Programs, such as County Medical Services (CMS)
More informationChapter 1.4. Intermittent neuroleptic treatment is a risk factor for tardive dyskinesia
Intermittent neuroleptic treatment is a risk factor for tardive dyskinesia The Curaçao Extrapyramidal Syndromes Study: III. Peter N. van Harten (1,3), Hans W. Hoek (2), Glenn E. Matroos (3), Maarten Koeter
More informationFormulary Item Restrictions and/or Advice Site availability
Formulary Item Restrictions and/or Advice Site availability C&W CNWL Typical Antipsychotic drugs Chlorpromazine 25mg Chlorpromazine 50mg Chlorpromazine 100mg Chlorpromazine 25mg/5ml syrup Chlorpromazine
More informationUniversity of Groningen. Metabolic risk in people with psychotic disorders Bruins, Jojanneke
University of Groningen Metabolic risk in people with psychotic disorders Bruins, Jojanneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationPlasma tenofovir trough concentrations are associated with renal dysfunction in Japanese patients with HIV infection: a retrospective cohort study
Kunimoto et al. Journal of Pharmaceutical Health Care and Sciences (2016) 2:22 DOI 10.1186/s40780-016-0056-5 RESEARCH ARTICLE Open Access Plasma tenofovir trough concentrations are associated with renal
More informationAssessing Conformance to Medication Treatment Guidelines for Schizophrenia in a Community Mental Health Center (CMHC)
Community Mental Health Journal, Vol. 39, No. 6, December 2003 ( 2003) Assessing Conformance to Medication Treatment Guidelines for Schizophrenia in a Community Mental Health Center (CMHC) Mona Goldman,
More informationAripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)
1. Key Points. Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1.1 Aripiprazole long acting injection (LAI) is licensed / indicated
More informationQuetiapine Case 2 Therapeutic Drug Monitoring Jose de Leon, MD
Quetiapine Case 2 Therapeutic Drug Monitoring 1-27-16 Jose de Leon, MD 2. Quetiapine Case Therapeutic Drug Monitoring (unpublished) Educational Objectives At the conclusion of this presentation, the participant
More informationEfficacy and safety of brexpiprazole for the treatment of acute. schizophrenia: a 6-week, randomized, double-blind, placebocontrolled
Supplementary material Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week, randomized, double-blind, placebocontrolled trial Christoph U. Correll, M.D. 1, Aleksandar
More informationPharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
(2004) 9, 442 473 & 2004 Nature Publishing Group All rights reserved 1359-4184/04 $25.00 www.nature.com/mp FEATURE REVIEW Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic
More informationReduced telaprevir dosing in combination therapy for patients with chronic hepatitis C
Original Contribution Kitasato Med J 2017; 47: 1-9 Reduced telaprevir dosing in combination therapy for patients with chronic hepatitis C Wataru Ando, 1 Yumi Fukunaga, 1 Hiroaki Yokomori, 2 Takako Komiyama
More informationRexulti (brexpiprazole)
Market DC Rexulti (brexpiprazole) Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Indiana see State Specific Mandates below *Maryland see State Specific Mandates below *Virginia
More informationAntipsychotics Prescribing Patterns of Patients with Schizophrenia Admitted to Korean General Hospital Psychiatric Unit: 2001 to 2008
Original Article pissn 1738-1088 / eissn 2093-4327 Clinical Psychopharmacology and Neuroscience 2011;9(1):17-22 Copyrightc 2011, Korean College of Neuropsychopharmacology Antipsychotics Prescribing Patterns
More informationPlatforms for Performance: Clinical Dashboards to Improve Quality and Safety 2011 Midyear Clinical Meeting
Improving Mental Health Outcomes in Veterans Through Dashboard Technology Learning Objectives 1. Describe VA Academic Detailing 2. Show how an increase in metabolic monitoring and a decrease in off-label
More informationAPPLYING ANTIPSYCHOTIC PHARMACOKINETICS TO BEST DOSING PRACTICES: DEPOT MEDICATIONS
APPLYING ANTIPSYCHOTIC PHARMACOKINETICS TO BEST DOSING PRACTICES: DEPOT MEDICATIONS Objectives Review the kinetic parameters of depot antipsychotics Review loading strategies for those depot medications
More informationAggression (Severe) in Children under Age 6
Aggression (Severe) in Children under Age 6 Level 0 Comprehensive diagnostic assessments. Refer to Principles of Practice on page 6. Evaluate and treat comorbid conditions (i.e. medical, other psychiatric
More informationI received help from Bosch Health Care
John Kasckow, MD, PhD VA Pittsburgh Health Care System Western Psychiatric Institute and Clinic, UPMC VA Pittsburgh Health Care System I received help from Bosch Health Care 1 Diagnoses of Interest Early
More informationQuetiapine Case 1 Warfarin Jose de Leon, MD
Quetiapine Case 1 Warfarin 1-23-16 Jose de Leon, MD 1. Quetiapine Case 1 J Clin Psychopharm 1999;19:382-3 http://www.ncbi.nlm.nih.gov/pubmed/10440472 Educational Objectives At the conclusion of this presentation,
More informationSchizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
More informationUse of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia
Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia Aine Leen, Kieran Walsh, David O Sullivan, Denis O Mahony, Stephen Byrne, Margaret Bermingham Pharmaceutical Care Research Group,
More informationMinimising the Impact of Medication on Physical Health in Schizophrenia
Minimising the Impact of Medication on Physical Health in Schizophrenia John Donoghue Liverpool Imagination is more important than knowledge Albert Einstein LIFESTYLE Making choices TREATMENT Worse Psychopathology,
More informationMethod. NeuRA Paliperidone August 2016
Introduction Second generation antipsychotics (sometimes referred to as atypical antipsychotics) are a newer class of antipsychotic medication than first generation typical antipsychotics. Second generation
More informationGenetics and Genomics: Influence on Individualization of Medication Regimes
Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics
More informationAPRIL 2008 DELHI PSYCHIATRY JOURNAL Vol. 11 No.1. Harish Arora, Rajdeep Kaur Department of Psychiatry, G.G.S. Medical College, Faridkot, Punjab
APRIL 2008 DELHI PSYCHIATRY JOURNAL Vol. 11 No.1 Original Article An Open Label Study on Amisulpride in Augmentation with Atypical Antipsychotics in Treatment Resistant Patients of Schizophrenia and Schizoaffective
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationThe safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
Nasrallah et al. BMC Psychiatry (2017) 17:305 DOI 10.1186/s12888-017-1459-z RESEARCH ARTICLE The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega Sustenna, Invega Trinza) Reference Number: CP.PHAR.291 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationIs Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Aristada (Aripiprazole Lauroxil)
More informationWESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS
WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information